Page 220 - FBL AR 2019-20

Fermenta Biotech Limited
Annual Report 2019-20

Notes to the Consolidated financial statements for the year ended March 31, 2020

45 Segment information: (contd.)

( H in Lakhs )
2019-2020
2018-2019
Bulk Drug/Chemicals Property Total
- unallocated segment tangible and intangible assets -
50.10
8. Depreciation and amortization expense 1,126.73 356.58 1,483.31
809.13 349.77 1,158.90
9 Unallocated depreciation 16.66
29.85

(Figures in italics are the corresponding figures in respect of the previous year.)
B) Geographical information
Geographical information is reported on the basis of the geographical location of the customers. The management views the Indian
market and export markets as distinct geographical markets.

Revenue by market – The following is the distribution of the Group’s revenue by geographical market:
( H in Lakhs )
March 31, 2020 March 31, 2019
India 4,907.42
Bulk Drug/Chemicals 8,420.14 8,587.42
Property 1,732.72 1,541.52
Europe - Bulk Drug/Chemicals 8,635.50 21,276.47
USA - Bulk Drug/Chemicals 3,002.28 4,369.68
Others countries - Bulk Drug/Chemicals 7,504.28 4,691.95
29,294.92 40,467.04

Assets by geographical area – The following is the carrying amount of segment non-current assets by geographical area in which the
assets are located:
( H in Lakhs )
Non-Current assets*
March 31, 2020 March 31, 2019
India
Bulk Drug/Chemicals 17,687.93 10,602.93
Property 8,938.10 9,311.34
Europe
Bulk Drug/Chemicals 466.19 -
27,092.22 19,914.27

* Non-current assets exclude investments, loans, share application money, other financial assets, tax assets and other non current assets.
The Group has generated revenue aggregating H6,529.96 Lakhs from two customers (March 31, 2019 : H10,133.70 Lakhs from two
customers). Revenue from each of these customers is 10% or more of the group’s total revenue.
46 List of entities included in the consolidated financial statements is as under

Country of Incorporation Proportion of ownership interest as at
March 31, 2020 March 31, 2019
Parent Company:
Fermenta Biotech Limited (Formerly Known as DIL Limited) India
Subsidiaries
Aegean Properties Limited India 100.00% 100.00%
CC Square Films Limited India 100.00% 100.00%
Fermenta Biotech GmbH (w.e.f. September 05, 2019) Germany 100.00% -
Fermenta Biotech (UK) Limited United Kingdom 100.00% 100.00%
G.I. Biotech Private Limited India 62.50% 62.50%
Associate
Health and Wellness India Private Ltd India 47.15% 47.15%

218